Hologic Obtains CE Mark for Affirm® Contrast Biopsy Software
Hologic, Inc. (HOLX)
Last hologic, inc. earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.hologic.com
Company Research
Source: Business Wire
Innovative Technology Allows Clinicians to Target and Acquire Tissue Samples Using Contrast-Enhanced Mammography MARLBOROUGH, Mass.--(BUSINESS WIRE)--Global women’s health leader Hologic, Inc. (Nasdaq: HOLX) today announced that its Affirm® Contrast Biopsy Software, which combines contrast-enhanced diagnostic capabilities with accurate lesion targeting to help streamline workflow and accelerate biopsy procedures,1-2 is now CE-marked. The technology received clearance from the U.S. Food and Drug Administration in October 2020.Designed from the ground up to integrate with the Selenia® Dimensions® and 3Dimensions™ systems, Hologic’s Affirm Contrast Biopsy Software enables clinicians to target and acquire tissue samples in lesions identified through contrast-enhanced mammography (CEM).“At Hologic, we are committed to helping women live healthier lives everywhere, every day, including through innovative technologies that support the detection and diagnosis of breast cancer,” said Tanja
Show less
Read more
Impact Snapshot
Event Time:
HOLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOLX alerts
High impacting Hologic, Inc. news events
Weekly update
A roundup of the hottest topics
HOLX
News
- New Data to be Presented at the 2025 SABCS Demonstrates Potential Expanded Utility of the Breast Cancer Index Test, the Leading Biomarker in Personalizing Endocrine Therapy DurationBusiness Wire
- Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]Yahoo! Finance
- New Clinical Evidence on Hologic’s AI-Powered Mammography Solutions Will Be Unveiled at RSNABusiness Wire
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-HOLX, MOFG, NIC, and AWKPR Newswire
- Hologic (NASDAQ:HOLX) was downgraded by analysts at BNP Paribas Exane from an "outperform" rating to a "neutral" rating. They now have a $79.00 price target on the stock.MarketBeat
HOLX
Earnings
- 11/3/25 - Beat
HOLX
Sec Filings
- 12/12/25 - Form PREM14A
- 11/18/25 - Form 4
- 11/18/25 - Form 4
- HOLX's page on the SEC website